clinical trial · NCT06991101
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Baptist Health South Florida·phase2·recruiting·n = 190
GlioblastomaBrain CancerGlioblastoma MultiformeGlioblastoma Multiforme of BrainGlioblastoma Multiforme, AdultMGMT-Unmethylated GlioblastomaMGMT-Methylated GlioblastomaRuxolitinibTemozolomideRadiation Therapy
brief summary
The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to take the study drug ruxolitinib in addition to the standard of care temozolomide and radiation therapy and the other half will be assigned to the standard of care temozolomide and radiation therapy only. This assignment will be randomized in a 1-to-1 ratio, like the flip of a coin.
started
Dec 3, 2025
primary completion
Dec 1, 2030
completion
Dec 1, 2030
last updated
Dec 26, 2025
official title
Randomized Phase 2 Trial of Ruxolitinib in Combination With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol